ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Colorado's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
RMOS Educational Award
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
RMOS Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Read the full FDA press release here
Tweets by OSSatACCC